University of Montreal
Neuroscience
Dr. Di Polo is a Professor in the Departments of Neuroscience and Ophthalmology at the University of Montreal (Quebec, Canada) and currently holds a Canada Research Chair in glaucoma and age-related neurodegeneration. She completed her Bachelor of Science in biology from the Universidad Central de Venezuela (Caracas, Venezuela) and her PhD in physiology from the University of California (Los Angeles, USA; Supervisor: Dr. Deborah Farber). Dr. Di Polo then pursued postdoctoral training at the Center for Research in Neuroscience at McGill University (Quebec, Canada; Supervisor: Dr. Albert Aguayo). Dr. Di Polo’s research program focuses on understanding mechanisms of neuronal, glial, and vascular deficits in glaucoma. The ultimate goal of her laboratory is to develop regenerative therapies to restore retinal ganglion cell function and, ultimately, vision in patients affected by glaucoma. She has received continuous research funding throughout her career and is presently Principal Investigator on grants from the Canadian Institutes of Health Research, National Institutes of Health, Department of Defense USA, and other competitive grants and awards from non-profit organizations as well as industry. Dr. Di Polo serves on numerous national and international committees. She is the current Director of the Retina and Posterior Segment Group of the Quebec Vision Health Research Network and will serve as the Canadian Association for Neuroscience (CAN) President in 2023-2024. She is an ARVO Gold Fellow since 2015. Recent accomplishments include the 2019 Shaffer Prize from the Glaucoma Research Foundation and the Lewis Rudin Glaucoma Research Prize awarded in 2020.

Moderator of 1 Session

PRE CONFERENCE SYMPOSIUM
Session Time
08:00 - 15:50
Session Type
PRE CONFERENCE SYMPOSIUM
Date
Tue, 28.03.2023
Room
ONSITE - HALL G3
Session Description
This day-long, CME credit-eligible workshop will provide participants with an understanding of the common and distinct features of neurodegenerative diseases, which include not only those affecting the brain, such as Alzheimer’s disease, Parkinson’s disease, dementia with Lewy bodies, vascular dementia, frontotemporal dementia, and mixed dementia; but also the ocular diseases including age-related macular degeneration, glaucoma, diabetic retinopathy, and inherited retinal degenerative diseases. Some questions that will be addressed during this fourth pre-symposium workshop, starting from small (Section 1. Mitochondria In Health and Neurodegeneration; and Section 2. Glucose and Lipid Metabolism) and ending with a more wholistic (Section 3. System-level Energy Dysfunction and Metabolic Disorders) point of view: •Why does the nervous system (including the brain and eyes) have a unique energy demand? •How can one evaluate metabolic fitness? •How can only tiny changes in energy, metabolism and/or mitochondria lead to neurodegenerative disease?•Is there a definite ‘tipping point’ that could be prevented in humans to delay onset of disease?•What role do comorbidities, like diabetes and other insulin/energy/metabolism-dysfunction diseases, play in neurodegenerative diseases?•How can one study this in living humans? •Are there common elements across these diseases that could give a clue to preventions and future treatments?Section 1 Summary: Mitochondria are essential organelles that regulate multiple processes essential for neuronal function including metabolic balance, intracellular calcium homeostasis, production of reactive oxygen species, and apoptotic signaling. Accumulating evidence indicates that mitochondrial defects play a central role in the pathogenesis of neurodegenerative diseases. This session will cover new insights into mitochondrial dynamics, trafficking, transmitophagy, and damage as well as novel therapeutic strategies to increase mitochondrial health in eye and brain diseases.Section 2 Summary: Individual cell-types in the brain have unique energy requirements and unique roles in meeting the energetic demands placed on the brain. Disruption in cellular cross-talk and cell-autonomous energy occur during the setting of neurodegenerative disease. A more refined disruption of the cellular and intercellular metabolic defects will likely offer new insights into neurodegenerative disease and perhaps illuminate novel therapeutic approaches.Section 3 Summary: Metabolic conditions and diabetes are risk factors for both Alzheimer’s disease and eye diseases. In addition to hypoperfusion restricting blood flow, they also impact brain energy metabolism including insulin signaling and glucose utilization. In this section, the speakers will discuss how brain metabolism and insulin signaling are impaired in these neurodegenerative conditions and how these pathways can be targeted for therapy to treat brain and eye diseases, and to promote healthy brain aging.

Supported with an educational grant by BrightFocus

Presenter of 3 Presentations